Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00876395 · ClinicalTrials.gov registry record · Phase 3
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 719
- Enrollment target
NCT00876395 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 719 participants.
The verdict
NCT00876395, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 719 participants
- Enrollment target
Study Summary
The purpose of this Phase III study was to confirm the value of adding everolimus to weekly paclitaxel and trastuzumab as treatment of HER2-overexpressing metastatic breast cancer.
Interventions
- DRUG Trastuzumab
- DRUG Placebo
- DRUG Paclitaxel
- DRUG Everolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 719 participants |
| Start Date | 2009-09-10 |
| Est. Completion | 2017-10-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00876395
The ClinicalTrials.gov registry entry for NCT00876395 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 719 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Trastuzumab is the first listed.
NCT00876395 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00876395 about?
NCT00876395 is a clinical study titled "Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer". The purpose of this Phase III study was to confirm the value of adding everolimus to weekly paclitaxel and trastuzumab as treatment of HER2-overexpressing metastatic breast cancer.
What is the current status of trial NCT00876395?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 719 participants. The study started on 2009-09-10. Estimated completion is 2017-10-23.
What interventions are being tested in trial NCT00876395?
The interventions under investigation include: Trastuzumab (DRUG), Placebo (DRUG), Paclitaxel (DRUG), Everolimus (DRUG).
Who is sponsoring clinical trial NCT00876395?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.